HC Wainwright Estimates Sutro Biopharma Q2 Earnings

Sutro Biopharma, Inc. (NASDAQ:STRO) – Investment analysts at HC Wainwright issued their Q2 2025 earnings estimates for Sutro Biopharma in a research note issued to investors on Monday, November 18th. HC Wainwright analyst A. Fein expects that the company will post earnings of ($0.87) per share for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Sutro Biopharma’s Q4 2025 earnings at ($0.96) EPS.

STRO has been the subject of several other reports. Piper Sandler restated an “overweight” rating and issued a $11.00 price target on shares of Sutro Biopharma in a research note on Friday, October 11th. Truist Financial lowered their price objective on shares of Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, August 16th. Finally, JMP Securities restated a “market outperform” rating and issued a $17.00 price target on shares of Sutro Biopharma in a research note on Monday, September 16th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Sutro Biopharma currently has a consensus rating of “Buy” and a consensus price target of $12.14.

Sutro Biopharma Stock Performance

Shares of STRO opened at $2.67 on Tuesday. Sutro Biopharma has a 52 week low of $2.13 and a 52 week high of $6.13. The firm has a market cap of $220.17 million, a P/E ratio of -1.66 and a beta of 1.17. The firm’s 50-day simple moving average is $3.64 and its 200 day simple moving average is $3.81.

Institutional Trading of Sutro Biopharma

Institutional investors have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. lifted its holdings in Sutro Biopharma by 1,606.1% in the second quarter. Point72 Asset Management L.P. now owns 4,447,634 shares of the company’s stock valued at $13,032,000 after buying an additional 4,186,938 shares during the period. Bank of Montreal Can acquired a new position in shares of Sutro Biopharma during the third quarter valued at about $2,852,000. Jacobs Levy Equity Management Inc. boosted its position in shares of Sutro Biopharma by 214.3% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,069,522 shares of the company’s stock worth $6,043,000 after purchasing an additional 729,239 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Sutro Biopharma in the 3rd quarter valued at about $1,512,000. Finally, Acadian Asset Management LLC raised its stake in Sutro Biopharma by 30.8% during the 2nd quarter. Acadian Asset Management LLC now owns 1,574,958 shares of the company’s stock worth $4,613,000 after buying an additional 370,705 shares during the period. 96.99% of the stock is currently owned by institutional investors.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.